Cosmo Pharmaceuticals NV
SIX:COPN
Cosmo Pharmaceuticals NV
SIX:COPN
Price:
70.8 CHF
0.43%
Market Closed
Updated:
Jun 2, 2024
Cosmo Pharmaceuticals NV
Operating Income
|
Cosmo Pharmaceuticals NV
Operating Income Peer Comparison
Comparables:
PRGO
JAZZ
AVDL
G
GHRS
OVB
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Operating Income
€12.2m
|
CAGR 3-Years
61%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Operating Income
$221.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-10%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Operating Income
$518.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
10%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Operating Income
-$148.7m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-9%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Operating Income
-$41.2m
|
CAGR 3-Years
-351%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Operating Income
-€2.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
12%
|
See Also
What is Cosmo Pharmaceuticals NV's Operating Income?
Operating Income
12.2m
EUR
12.2m
EUR
Based on the financial report for Dec 31, 2023, Cosmo Pharmaceuticals NV's Operating Income amounts to 12.2m EUR.
What is Cosmo Pharmaceuticals NV's Operating Income growth rate?
Operating Income CAGR 10Y
-1%
-1%
Over the last year, the Operating Income growth was -56%. The average annual Operating Income growth rates for Cosmo Pharmaceuticals NV have been 61% over the past three years , and -1% over the past ten years .
You don't have any saved screeners yet
